Volastra
Business Services · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1361 Amsterdam Ave Ste 520, New York Cit...Phone Number
(646) 344-1248Website
www.volastratx.comRevenue
$11.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Volastra
Volastra is a biotechnology company developing novel therapies to treat and prevent the formation of metastatic disease. Established in 2019, Volastra is headquartered in New York, United States.Explore more
Volastra Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Volastra your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Volastra
Earning: See what the market has to say on Volastra recently announced quarterly report
Check if Volastra has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Volastra has new funding data
Product Launch: Get notified when Volastra launches new products
Volastra, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Volastra had a recent Job posting/layoffs
Check out if Volastra is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Volastra as Masked Content
Find 3 more new buyers
Compare Similar Companies to Volastra
Compare insights from companies similar to Volastra, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Volastra is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Volastra is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Volastra.
Volastra financials insights
Gather financial insights about Volastra, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Angel/Seed
$44M
2023
Series A
$60M
2025
Private Equity
$30.1M
Volastra Tech Stack
A closer look at the technologies used by Volastra
Most Recent Scoops
Open Position
Open Position
Funding
Funding
Open Position
Lateral Move
Executive Move
Executive Moves, Lateral Move
Volastra News & Media
Volastra Therapeutics Announces Appointment of David P. Southwell as Chief Executive Officer
NEW YORK, May 27, 2025--Volastra Therapeutics, a clinical-stage cancer biotechnology company, today announced the appointment of David P. Southwell as Chief Executive Officer. Mr. Southwell brings over 30 years of C-level executive biotechnology experience to Volastra as the company continues to advance its pipeline, which is led by two novel clinical stage KIF18A inhibitors.Volastra Announces Initial Data from First-in-Human Phase I/II Trial of Novel KIF18A Inhibitor VLS-1488 to be Presented at 2025 ASCO Annual Meeting
NEW YORK--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on chromosomal instability, today announced preliminary safety and efficacy data from its ongoing, first-in-human Phase I/II trial of its novel, oral KIF18A inhibitor, VLS-1488. These results will be featured in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 2. “We are excited by these results from our VLS-1488 KIF18A inhibitor proVolastra Therapeutics Announces the Appointment of Co-Founder Samuel Bakhoum, M.D., Ph.D., as Chief Scientific Officer
NEW YORK--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage biotechnology company pioneering novel approaches to treating cancer by targeting chromosomal instability, today announced the appointment of Volastra Co-Founder, Samuel Bakhoum, M.D., Ph.D., as its Chief Scientific Officer (CSO). Dr. Bakhoum, a renowned physician-scientist and leading expert in cancer research, joins Volastra’s management team from Memorial Sloan Kettering Cancer Center (MSKCC) in New York, where he led a reseaVolastra Therapeutics Granted FDA Fast Track Designation for Novel KIF18A Inhibitor in Ovarian Cancer
NEW YORK--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VLS-1488, the company’s internally discovered KIF18A inhibitor. The designation has been granted for the treatment of patients with platinum-resistant high-grade serous ovarian cancer (HGSOC). “Platinum-resistant high-grade serous ovarian cancer is marked by poor prognosis, highlighting the urgent need fo
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Volastra
Sign Up For FreeTo access detailed company insights
Volastra is a biotechnology company developing novel therapies to treat and prevent the formation of metastatic disease. Established in 2019, Volastra is headquartered in New York, United States.... Read More
